Accelerate patient access to cell and gene therapies
What if you could shorten the time it takes to activate apheresis and cell collection sites to begin collecting starting material for your cell or gene therapy and simultaneously create efficiencies for those sites?
With QSAP, one organization audits each center one time over an established timeframe, such as every two years. Cell and gene therapy companies license the audit results from the auditing organization, alleviating the necessity for multiple companies to conduct individual, yet similar, audits at the same sites.
Therapy developers can more rapidly move sites from qualification to activation. And, collection centers can spend less time on audit activities and more time collecting high-quality starting material for therapy manufacturing and delivery to patients.
The result? Patients get access to new cell and gene therapies sooner.
NMDP BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the industry-leading experience of NMDP, and a research partnership with the CIBMTR® (Center for International Blood and Marrow Transplant Research®), the organization designs solutions that advance the development of cell and gene therapies across the globe.
NMDP BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cellular source material from the NMDP Registry, the world’s most diverse registry of more than 22 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection, and transplant centers worldwide, the organization develops, onboards, trains, and manages expansive collection networks to advance cell therapies. NMDP BioTherapies uses a proven infrastructure consisting of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to transport and deliver regulatory-compliant life-saving therapies across the globe successfully. Through the CIBMTR, NMDP BioTherapies extends services beyond the cell therapy supply chain to include long-term follow-up tracking for the first two FDA-approved CAR-T therapies.
